Building better T-cell-inducing malaria vaccines

Immunology

Volumn 115, Issue 2, 2005, Pages 163-169

  Todryk, Stephen M ^a   Walther, Michael ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Malaria; T cell; Vaccines

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; ICC 1132; IMMUNOLOGICAL ADJUVANT; LIVER STAGE ANTIGEN 3; MALARIA VACCINE; MULTIEPITOPE THROMBOSPONDIN RELATED ADHESION PROTEIN; PLASMID DNA; PROTEIN FP9; QS 21; RECOMBINANT ANTIGEN; RECOMBINANT DNA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS VECTOR;

ADULT; ANTIGEN EXPRESSION; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; EFFECTOR CELL; ENDEMIC DISEASE; ERYTHROCYTE; FEMALE; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LIFE CYCLE; LIVER CELL; MALARIA; MALE; MORTALITY; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SPOROZOITE; T LYMPHOCYTE; VACCINATION;

ANIMALS; HUMANS; IMMUNITY, CELLULAR; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; T-LYMPHOCYTES;

EID: 19544385622     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2005.02154.x     Document Type: Review

References (50)

1. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria. Past, present, and future. Lancet Infect Dis 2004; 4:327-36.
2. Schofield L, Ferreira A, Altszuler R, Nussenzweig V, Nussenzweig RS. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J Immunol 1987; 139:2020-5.
3. Hill AV, Elvin J, Willis AC et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992; 360:434-9.
4. Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. J Immunol 2000; 165:1453-62.
5. Moorthy VS, Good MF, Hill AV. Malaria vaccine developments. Lancet 2004; 363:150-6.
6. Moore AC, Hill AV. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 2004; 199:126-43.
7. Ballou WR, Arevalo-Herrera M, Carucci D et al. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 2004; 71:239-47.
8. Knolle PA, Gerken G. Local control of the immune response in the liver. Immunol Rev 2000; 174:21-34.
9. Urban BC, Ferguson DJ, Pain A, Willcox N, Plebanski M, Austyn JM, Roberts DJ. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 1999; 400:73-7.
10. Xu H, Wipasa J, Yan H, Zeng M, Makobongo MO, Finkelman FD, Kelso A, Good MF. The mechanism and significance of deletion of parasite-specific CD4(+) T cells in malaria infection. J Exp Med 2002; 195:881-92.
11. Omer FM, de Souza JB, Corran PH, Sultan AA, Riley EM. Activation of transforming growth factor beta by malaria parasite-derived metalloproteinases and a thrombospondin-like molecule. J Exp Med 2003; 198:1817-27.
12. Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 1988; 85:573-6.
13. Rodrigues MM, Cordey AS, Arreaza G, Corradin G, Romero P, Maryanski JL, Nussenzweig RS, Zavala F. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol 1991; 3:579-85.
14. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989; 341:323-6.
15. Hoffman SL, Isenbarger D, Long GW et al. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science 1989; 244:1078-81.
16. Renggli J, Hahne M, Matile H, Betschart B, Tschopp J, Corradin G. Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity. Parasite Immunol 1997; 19:145-8.
17. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393:474-8.
18. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421:852-6.
19. Li S, Rodrigues M, Rodriguez D, Rodriguez JR, Esteban M, Palese P, Nussenzweig RS, Zavala F. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 1993; 90:5214-18.
20. Rodrigues M, Li S, Murata K et al. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J Immunol 1994; 153:4636-48.
21. Plebanski M, Gilbert SC, Schneider J et al. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 1998; 28:4345-55.
22. Schneider J, Gilbert SC, Blanchard TJ et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998; 4:397-402.
23. Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, Sinden R, Hill AV. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002; 20:1039-45.
24. Anderson RJ, Hannan CM, Gilbert SC et al. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J Immunol 2004; 172:3094-100.
25. Pombo DJ, Lawrence G, Hirunpetcharat C et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002; 360:610-7.
26. Lee EA, Palmer DR, Flanagan KL et al. Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun 2002; 70:1417-21.
27. Artavanis-Tsakonas K, Tongren JE, Riley EM. The war between the malaria parasite and the immune system, immunity, immunoregulation and immunopathology. Clin Exp Immunol 2003; 133:145-52.
28. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 1973; 266:169-77.
29. Wizel B, Houghten R, Church P et al. HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers. J Immunol 1995; 155:766-75.
30. Stoute JA, Rester KE, Krzych U et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 1998; 178:1139-44.
31. Kester KE, McKinney DA, Tornieporth N et al. RTS,S Malaria Vaccine Evaluation Group. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 2001; 183:640-7.
32. Bojang KA, Milligan PJ, Pinder M et al. RTS,S Malaria Vaccine Trial Team. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001; 358:1927-34.
33. Reece WH, Pinder M, Gothard PK et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 2004; 10:406-10.
34. Flanagan KL, Mwangi T, Plebanski M et al. Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans. Longevity and risk of Plasmodium falciparum infection. Am J Trop Med Hyg 2003; 68:421-30.
35. Wang R, Epstein J, Charoenvit Y et al. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J Immunol 2004; 172:5561-9.
36. Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/ AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004; 364:1411-20.
37. Birkett A, Lyons K, Schmidt A et al. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun 2002; 70:6860-70.
38. Walther M, Dunachie S, Keating S et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132, formulated in Seppic ISA 720. Vaccine 2005; 23:857-64.
39. Daubersies P, Thomas AW, Millet P et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 2000; 6:1258-63.
40. Nardin EH, Oliveira GA, Calvo-Calle JM et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J Infect Dis 2000; 182:1486-96.
41. Moorthy VS, McConkey S, Roberts M et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003; 21:1995-2002.
42. McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9:729-35.
43. Bejon P, Andrews L, Andersen RF et al. Calculation of liver-to-blood inocula. Parasite growth rates and pre-erythrocytic vaccine efficacy from serial quantitative PCR studies of malaria sporozoite challengees. J Infect Dis in press.
44. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, Hill AVS. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 2005; 174:449-55.
45. Moorthy VS, Imoukhuede EB, Milligan P et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 2004; 1:128-36.
46. Moorthy VS, Imoukhuede EB, Keating S et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 2004; 189:2213-9.
47. Prieur E, Gilbert SC, Schneider J, Moore AC, Sheu EG, Goonetilleke N, Robson KJ, Hill AV. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proc Natl Acad Sci USA 2004; 101: 290-5.
48. Ockenhouse CF, Sun PF, Lanar DE et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998; 177:1664-73.
49. Epstein JE, Charoenvit Y, Kester KE et al. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine 2004; 22: 1592-603.
50. Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005; 433:164-7.